Fresenius (FMS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Shares in the world's largest kidney dialysis provider Fresenius Medical Care (FMC) plunged more than 12% to a 12-year low on Thursday after it cut its earnings outlook as costs surge and a U.S ...

The German healthcare company on Tuesday said it sold around 10.6 million shares, or around 3.6% of Fresenius Medical Care’s share capital, at a price of 44.50 euros a share.

While solid growth among Fresenius Kabi and Fresenius Helios in the third quarter helped drive overall sales 5% to about €10.46 billion ($10.36 billion), Vamed and FMC suffered in the face of a ...

Fresenius reported an above-forecast 13% rise in underlying profit for the fourth quarter and forecast further growth in earnings and sales this year, and an improved cost-savings target for 2025.

Transformation should be completed quickly, without getting lost in the minutiae, says Ingo Elfering, group CIO of Fresenius. “It’s better to do it quickly, like taking a Band-Aid off, even if ...

Fresenius SE raised close to €1.1 billion ($1.2 billion) in a sale of shares in Fresenius Medical Care AG as well as exchangeable bonds linked to the dialysis firm, as it looks to cut debt and ...

Fresenius Kabi Iodixanol Injection, USP is currently available in six presentations for intra-arterial and intravenous procedures: 270 mg Iodine per mL: 100 mL polymer bottle ...

Fresenius Medical Care treats end-stage renal disease, or ESRD, patients primarily through its dialysis clinic network and related medical technology. Its strengths in these related areas help ...

Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript U.S. dialysis volumes expected to rebound in 2024 despite GLP-1 impact Fresenius down 6% despite bottom-line beat ...

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.

Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).